Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,660,611	$ 20,637,045
Short-term investment securities	9,087,199	8,457,452
Interest receivable	74,793	112,247
Accounts receivable	179,632	294,199
Prepaid expenses and other current assets	569,965	280,555
Total current assets	23,572,200	29,781,498
Non-current assets:
Equity investment	284,709	284,709
Other assets	6,143	6,225
Total assets	23,863,052	30,072,432
Current liabilities:
Accounts payable	957,802	1,013,099
Accrued expenses	842,450	489,756
Deferred research and development obligations	162,680	123,016
Total current liabilities	1,962,932	1,625,871
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding	0	0
Common stock, $.001 par value:Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021, and December 31, 2020, respectively	40,333	39,748
Additional paid-in capital	100,322,444	98,013,079
Treasury stock, shares held at cost - 12,253,502	(18,929,915)	(18,929,915)
Accumulated deficit	(59,532,742)	(50,676,351)
Total stockholders’ equity	21,900,120	28,446,561
Total liabilities and stockholders’ equity	$ 23,863,052	$ 30,072,432

Represents the current amount of prepaid research and development in process as of the balance sheet date.

No definition available.

Name:	dyai_PrepaidResearchAndDevelopmentInProcessCurrent
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).